logo
A trichologist's guide to thickening your hair without hormones

A trichologist's guide to thickening your hair without hormones

Yahoo23-05-2025

Experiencing a thinner ponytail or less bounce at your roots? You're not alone.
Hair naturally sheds more and thins as we age. While hormonal changes often contribute, several non-hormonal strategies can restore thickness and fullness.
Trichologists and celebrity hair experts weigh in on why hair changes and how to revitalize body and volume – without hormone intervention.
One key factor is the shrinking of hair follicles with age, leading to finer strands and a thinner overall appearance. Additionally, the hair growth cycle loses efficiency over time.
'Everyone's hair loses volume to a certain degree with age,' explains Philip Kingsley's lead trichologist Anabel Kingsley. 'Just like we don't have the same skin tone in our 40s, 50s and beyond as we did in our 20s, our scalp and hair follicles age – which impacts the quality of strands they produce. Hairs become finer and fewer hairs are growing in relation to resting and shedding.'
Hormonal shifts – especially during perimenopause and menopause – can play a big part. 'The biggest time to see loss of hair volume is during perimenopause and menopause,' says Kingsley.
'This is due to declining oestrogen levels. Oestrogen is very hair supportive; it's anti-inflammatory and helps to keep hairs in their growth – the anagen – phase for longer.
'When oestrogen declines, it can cause more hairs to shed, as well as make them finer and shorter.'
These hormonal changes, combined with reduced blood circulation to the scalp and slower cell regeneration, all contribute to hair thinning.
Fortunately, thinning hair doesn't mean you're out of options. Several non-hormonal treatments can support scalp health and stimulate hair growth.
'Topical or oral minoxidil is generally the most effective non-hormonal treatment for female pattern hair loss,' explains Kingsley. 'Micro-needling may also help – but I would suggest having this done at a dermatologist to avoid damaging your scalp. It's most effective when used alongside Minoxidil.'
Minoxidil is a topical treatment that you can apply to your scalp to stimulate hair growth but can take two to four months to see its effects. It also maintains the regrowth, meaning when you stop using it, the regrown hair can fall out within three months.
However, more natural ingredients can also stimulate hair growth. 'Topical melatonin, caffeine and peptide blends [also work],' explains Kingsley. 'While these won't be as effective as a medicated treatment, they can help.'
Inanch Emir, co-founder of Inanch London and hair extension specialist, supports this view, adding: 'Peptide – or stem cell-based serums – stimulate follicle activity.
'Caffeine-infused products may help energise roots. Biotin, niacin and zinc supplements also support healthy hair from within.'
She also says topical rosemary oil – which you may have seen on TikTok – has been shown in some studies to perform comparably to Minoxidil.
Regaine For Women 5% Scalp Foam 4 Months Supply, £34.32 (was £50), Just My Look
The Ordinary Multi-Peptide Serum for Hair Density, £20.80, Space NK
Nature Spell Rosemary Oil For Hair & Skin, £8, Holland and Barrett
Can routine and scalp care really make a difference?
While products are important, your daily habits and how you treat your scalp can play a key role in hair health and maintaining thickness.
'Scalp massages won't grow you a new head of hair, but it can support scalp health by reducing stress, encouraging healthy blood flow and relieving tension,' says Kingsley.
However, she warns against using scalp brushes, and instead use your fingertips. '[Scalp brushes] can break your hair and damage your scalp – plus they tend to get mouldy.'
Emir also stands by incorporating scalp and head massages into your routine: 'Scalp massaging for three to five minutes daily boosts blood flow, helping nutrient delivery to follicles,' she explains. Micro-needling, in a clinical setting, can also help by enhancing the absorption of growth serums to stimulate follicles.
But remember, sometimes less is more. Stick to gentle shampoos and finish with a cold rinse to enhance shine and scalp tone.
The right cut and styling can make a world of difference. Whether you're aiming to create the illusion of more volume or maximise what you have, small tweaks go a long way.
'I recommend using plumping shampoos to make the appearance fuller,' says Kingsley. 'Blow-drying your hair upside down or against the grain of growth can add lovely root lift.
'Volumising products are also great – use a root-boosting foam or froth to add root volume and spritz a thickening protein spray throughout your mid-lengths and ends to add texture.'
As for hair cuts, 'regular trims are essential for finer hair to get rid of any split ends and damage that makes hair look thinner,' says British Hairdresser of the Year and Toni & Guy's global creative director, Cos Sakkas.
'A blunt cut will make hair look thicker as it's denser through the outline. Layers cut in the correct way will help to create volume and shape, but it's important to keep the perimeter heavy and full throughout.'
Using volumising products after washing give an instant appearance of thicker-looking hair.
'Adding volume at the root will instantly make hair look and feel thicker,' says Sakkas.
'Blow-dry hair upwards away from the root […] tip it upside down in a diffuser if you're wanting a more naturally textured finish. Switch up your parting – wear it on the opposite side to your usual parting and you will instantly notice volume through the front.'
Philip Kingsley Body Builder Weightless Shampoo, £28
Philip Kingsley Body Builder Weightless Conditioner, £28
LABEL.M Volume Foam, £25, Toni and Guy

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'This is fantastic news for our NHS trust' - hospital trust gets £6.5 million
'This is fantastic news for our NHS trust' - hospital trust gets £6.5 million

Yahoo

time31 minutes ago

  • Yahoo

'This is fantastic news for our NHS trust' - hospital trust gets £6.5 million

A YORK hospital trust is set to get £6.5 million in Government funding to help fix its crumbling buildings. York and Scarborough Teaching Hospitals NHS Foundation Trust - which runs hospitals in York, Selby, Malton, Scarborough and Bridlington, is getting £6.5 million from the national Estates Safety Fund as part of the Government's mission to fix public service infrastructure through its Plan for Change. The money is going to hospitals and schools across the country and includes works to the roof as well as improvements to the internal and external building fabric and fixtures at Scarborough Hospital. Mayor of York and North Yorkshire, David Skaith said: "For too long, people have had to put up with leaking hospital roofs, crumbling classroom walls, and public buildings left to decay. Staff working in rundown facilities. "Children learning in classrooms patched up year after year. Patients treated in spaces that are barely fit for purpose. It's not good enough and people deserve so much better. "That's why I welcome the news that over £8 million is being invested in our hospitals in Scarborough, York and Harrogate, alongside millions more for schools - including in our region - as part of a Government programme to make public buildings fit for the future. "Our NHS staff, our children, and their teachers deserve so much better than a decade of decline. This is just the first step - but we're committed to rebuilding the modern, safe, and dignified public services our communities deserve.' Scarborough Hospital The Government says that fixing the backlog of maintenance at NHS hospitals will help prevent operation cancellations. Luke Charters, MP for York Outer, said the investment will help improve hospital infrastructure, enhance patient safety, and support vital upgrades to ensure high-quality healthcare delivery for local communities. 'This is fantastic news for our local NHS trust. I'm proud to support the hardworking staff at York and Scarborough hospitals, who go above and beyond every day for patients. This funding will make a real difference — it will improve safety, modernise our buildings and help ensure our hospitals can continue delivering for residents across York," he said. "Investment in our local NHS is not just investment in buildings – it's investment in the health and wellbeing of everyone in York. I will continue to fight for further support to make sure our local health services get the backing they need. "This extra investment comes from the Estates Safety Fund, a national strategy to upgrade and maintain hospital facilities ensuring that NHS buildings can adapt to future healthcare demands. "This alongside waiting lists coming down for 6 months in a row, is the true difference a Labour government makes."

British Airways flight attendant ‘found naked and dancing in business class toilet' after allegedly taking drugs
British Airways flight attendant ‘found naked and dancing in business class toilet' after allegedly taking drugs

Yahoo

time42 minutes ago

  • Yahoo

British Airways flight attendant ‘found naked and dancing in business class toilet' after allegedly taking drugs

A naked British Airways crew member was discovered dancing in a business class toilet while on shift mid-flight after allegedly taking drugs, according to reports. The Sun reported the steward was supposed to be serving meals to passengers on a recent flight from San Francisco to London Heathrow, but had disappeared. When the double-decker Airbus A380-800 was searched, it is claimed that the in-flight crew manager discovered him naked and dancing in the Club World cabin toilet. Staff reportedly dressed their colleague in a spare pair of pyjamas used by first-class passengers before buckling him into a first-class seat, where he stayed for the remainder of the 10-and-a-half-hour trip. The Metropolitan Police said a 41-year-old man on a flight from San Francisco to London Heathrow Airport was arrested on suspicion of being unfit for duty. The force said officers were called by cabin crew over concerns for the welfare of a man just after 9.30am. When the plane landed, he was taken to hospital for treatment, before being arrested and later released under investigation as enquiries continue. British Airways told The Independent the incident is a matter for the police. The Met said in a statement: 'At 9.32am, police based at Heathrow Airport were called by cabin crew following the concern for welfare of a man on an inbound flight from San Francisco. 'A 41-year-old man was taken to hospital for treatment once the flight had landed. 'Officers arrested the man after he received medical attention. He was arrested on suspicion of being unfit for duty. He has since been released under investigation. 'Enquiries remain ongoing into the circumstances, and an investigation has been launched.'

Addiction Disorders Drugs Market Analysis and Forecast to 2030: A $39.5 Billion Opportunity Led by Pfizer, Johnson & Johnson, and Indivior
Addiction Disorders Drugs Market Analysis and Forecast to 2030: A $39.5 Billion Opportunity Led by Pfizer, Johnson & Johnson, and Indivior

Yahoo

timean hour ago

  • Yahoo

Addiction Disorders Drugs Market Analysis and Forecast to 2030: A $39.5 Billion Opportunity Led by Pfizer, Johnson & Johnson, and Indivior

Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Addiction Disorders Drugs Market by Indication, Product Type, Route of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030" report has been added to Addiction Disorders Drugs Market grew from USD 27.08 billion in 2024 to USD 28.89 billion in 2025. It is expected to continue growing at a CAGR of 6.48%, reaching USD 39.49 billion by the past decade, the addiction therapeutics landscape has undergone profound transformation, propelled by breakthroughs in neuroscience and a heightened emphasis on personalized medicine. Digital therapeutics and telehealth solutions have augmented traditional pharmacotherapy, facilitating patient adherence and extending the reach of evidence-based care. Concurrently, the approval of novel opioid antagonists and long-acting formulations has redefined maintenance strategies, enabling clinicians to tailor regimens with greater these advancements, societal attitudes toward addiction are shifting, reducing stigma and encouraging earlier intervention. Collaborations between payers and providers are driving value-based payment models, incentivizing outcomes rather than volume. Moreover, regulatory agencies are streamlining approval pathways for therapies targeting high-unmet-need indications, accelerating time to market. These transformative shifts underscore a broader trend toward integrated, patient-centric frameworks that prioritize holistic recovery over symptom the Ripple Effects of 2025 US Tariff Policies on Drug Supply ChainsIn 2025, the introduction of new United States tariffs on active pharmaceutical ingredients and drug imports has generated ripple effects across the supply chain. Manufacturers dependent on overseas raw materials have confronted increased production costs, prompting adjustments in pricing strategies and contract negotiations. These cost pressures have been most pronounced for generics and off-patent formulations, where margins are inherently mitigate the impact, several stakeholders have diversified supplier networks, exploring domestic sourcing and vertical integration initiatives. Some companies have accelerated innovation pipelines to offset higher input costs through premium product launches. Meanwhile, payers and providers are recalibrating formularies to balance budgetary constraints with clinical efficacy, favoring therapies that demonstrate robust real-world outcomes. As the market adapts to this new tariff environment, agility and supply chain resilience have emerged as critical differentiators for industry Regional Dynamics Across the Americas, EMEA, and Asia-PacificRegional analysis reveals distinct market dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, high healthcare expenditure coupled with well-established regulatory frameworks fosters rapid uptake of innovative therapies, particularly in opioid and alcohol dependence. The convergence of public and private payer systems has also facilitated broad access initiatives, driving prescription volume Europe, Middle East and Africa, heterogeneity in healthcare infrastructure and reimbursement policies yields varied adoption rates. Western European markets emphasize evidence-based formulary inclusion and tend to favor branded medications, whereas emerging economies in the Middle East and Africa show heightened demand for cost-effective generic solutions. Collaborative agreements between local authorities and multinational corporations are instrumental in expanding treatment Asia-Pacific region is characterized by escalating investment in mental health programs and an accelerating shift toward outpatient care models. Nations such as Japan and Australia are pioneering long-acting injectable therapies, while Southeast Asian countries prioritize scalable, low-cost interventions. Regulatory reforms aimed at streamlining clinical trial processes are attracting significant R&D interest, positioning the region as a key growth Leading Stakeholders Steering Innovation and Market GrowthKey players are deploying multifaceted strategies to consolidate their market positions and advance therapeutic frontiers. Leading pharmaceutical companies have fortified their pipelines through acquisitions of biotech innovators specializing in novel receptor targets and long-acting delivery platforms. Strategic alliances are enabling the co-development of combination therapies that integrate pharmacological agents with digital adherence manufacturers are leveraging scale efficiencies to penetrate value-driven markets, while niche biotech firms concentrate on underserved indications and precision medicine approaches. Contract research organizations and specialty pharmacies have also emerged as vital partners, delivering integrated services that streamline patient onboarding and support adherence monitoring. The competitive landscape continues to evolve as emerging entrants pursue orphan drug designations and expedited approval pathways, challenging incumbents to maintain agility and clinical Pathways for Industry Leaders to Navigate Future ChallengesIndustry leaders should prioritize portfolio diversification by balancing established therapies with novel modalities that address unmet needs. Investment in real-world evidence generation will strengthen payer negotiations and support value-based contracting. Cultivating partnerships with digital health providers can amplify patient engagement and adherence metrics, enhancing clinical and economic chain resilience must be reinforced through dual sourcing strategies and advanced inventory management systems to mitigate tariff and geopolitical risks. Organizations are advised to explore regional manufacturing hubs to reduce import dependencies and shorten lead times. Engaging with regulatory bodies to shape policy frameworks will facilitate faster approval pathways and market access for innovative adopting patient-centric service models that integrate pharmacotherapy with psychosocial support will differentiate offerings in a crowded marketplace. Embedding predictive analytics into care delivery can anticipate relapse risks and tailor interventions, ensuring sustained patient recovery and long-term market Segmentation & CoverageThis research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations: Indication Alcohol Dependence Acamprosate Disulfiram Naltrexone Opioid Dependence Buprenorphine Methadone Naltrexone Smoking Cessation Bupropion Nicotine Replacement Therapy Gum Inhaler Lozenge Patch Varenicline Stimulant Dependence Off Label Drugs Research Drugs Product Type Branded Generic Route of Administration Injectable Intramuscular Intravenous Oral Sublingual Film Tablet Transdermal Patch Dosage Form Capsule Film Injectable Solution Patch Tablet Distribution Channel Hospital Pharmacy Online Pharmacy Retail Pharmacy End User Clinics Homecare Settings Hospitals This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions: Americas United States California Texas New York Florida Illinois Pennsylvania Ohio Canada Mexico Brazil Argentina Europe, Middle East & Africa United Kingdom Germany France Russia Italy Spain United Arab Emirates Saudi Arabia South Africa Denmark Netherlands Qatar Finland Sweden Nigeria Egypt Turkey Israel Norway Poland Switzerland Asia-Pacific China India Japan Australia South Korea Indonesia Thailand Philippines Malaysia Singapore Vietnam Taiwan The companies profiled in this Addiction Disorders Drugs market report include: Pfizer Inc. Johnson & Johnson Indivior plc Alkermes plc Camurus AB Orexo AB BioDelivery Sciences International, Inc. Titan Pharmaceuticals, Inc. Mallinckrodt plc Teva Pharmaceutical Industries Ltd. Key Attributes Report Attribute Details No. of Pages 196 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $28.89 Billion Forecasted Market Value (USD) by 2030 $39.49 Billion Compound Annual Growth Rate 6.4% Regions Covered Global For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store